Abstract 4140102: Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4140102
Abstract: Introduction: In patients with obstructive hypertrophic cardiomyopathy (oHCM), the SEQUOIA-HCM trial demonstrated that aficamten, a next-in-class cardiac myosin inhibitor, improved exercise capacity, heart failure symptoms and hemodynamics compared with placebo. Aficamten’s impact on overall quality-of-life… read more here.
Keywords: treatment; trial; sequoia hcm; obstructive hypertrophic ... See more keywords
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
Sign Up to like & getrecommendations! Published in 2025 at "Circulation. Heart failure"
DOI: 10.1161/circheartfailure.125.013918
Abstract: Background: Women with obstructive hypertrophic cardiomyopathy (oHCM) often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown. Methods: We performed a pre-specified subgroup… read more here.
Keywords: obstructive hypertrophic; sequoia hcm; women men; cardiomyopathy ... See more keywords
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Sign Up to like & getrecommendations! Published in 2025 at "Circulation"
DOI: 10.1161/circulationaha.124.073585
Abstract: BACKGROUND: Post-exercise oxygen uptake recovery (VO2Rec) is slow in advanced heart failure. We sought to establish easily derived VO2Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further… read more here.
Keywords: vo2t12; sequoia hcm; cardiac performance; exercise ... See more keywords